Search hospitals > California > San Francisco
University of California, San Francisco
Claim this profileSan Francisco, California 94110
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Prostate Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
2330 reported clinical trials
310 medical researchers
Summary
University of California, San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Cancer, Tumors, Prostate Cancer, Breast Cancer, Brain Tumor and other specialties. University of California, San Francisco is involved with conducting 2,330 clinical trials across 2,142 conditions. There are 310 research doctors associated with this hospital, such as Sabine Mueller, MD, PhD, MAS, Rahul Aggarwal, MD, Kieuhoa T. Vo, and Hope Rugo, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Tumors
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Sabine Mueller, MD, PhD, MASUniversity of California, San Francisco1 year of reported clinical research
Expert in Brain Tumor
Studies Recurrence
22 reported clinical trials
36 drugs studied
Rahul Aggarwal, MDUniversity of California, San Francisco4 years of reported clinical research
Expert in Prostate Cancer
Studies Cancer
24 reported clinical trials
36 drugs studied
Kieuhoa T. VoUCSF Medical Center-Mission Bay3 years of reported clinical research
Expert in Tumors
Studies Neuroblastoma
21 reported clinical trials
31 drugs studied
Hope Rugo, MDUniversity of California San Francisco4 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
19 reported clinical trials
45 drugs studied
Clinical Trials running at University of California, San Francisco
Multiple Myeloma
Surgical Site Infection
Breast Cancer
Parkinson's Disease
Psoriasis
Plasma Cell Neoplasms
Pancreatic Cancer
Hepatocellular Carcinoma
Liver Cancer
Coronavirus
DVRd + Ciltacabtagene Autoleucel / ASCT
for Multiple Myeloma
This trial is testing a combination of four drugs followed by either a special cell therapy or a stem cell transplant in newly diagnosed multiple myeloma patients who can have a transplant. The drugs fight cancer and boost immunity, while the cell therapy reprograms immune cells to attack cancer, and the stem cell transplant rebuilds bone marrow.
Recruiting4 awards Phase 34 criteria
bb2121
for Multiple Myeloma
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), in participants with multiple myeloma (MM) having progressed within 18 months of initial treatment with autologous stem cell transplantation (ASCT) (Cohort 2a) and without ASCT (Cohort 2b) or, in participants with inadequate response post ASCT during initial treatment (Cohort 2c) and the efficacy and safety of bb2121 used in combination with lenalidomide maintenance in participants with suboptimal response post ASCT (Cohort 3). Approximately 264 participants will be enrolled into one of three cohorts. Cohort 1 (including cohort 1b) will enroll approximately 126 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed multiple myeloma (NDMM) participants with suboptimal response to ASCT.
Recruiting3 awards Phase 25 criteria
Long-term Follow-up
for Cilta-cel in Multiple Myeloma
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Recruiting3 awards Phase 42 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of California, San Francisco?
University of California, San Francisco is a medical facility located in San Francisco, California. This center is recognized for care of Cancer, Tumors, Prostate Cancer, Breast Cancer, Brain Tumor and other specialties. University of California, San Francisco is involved with conducting 2,330 clinical trials across 2,142 conditions. There are 310 research doctors associated with this hospital, such as Sabine Mueller, MD, PhD, MAS, Rahul Aggarwal, MD, Kieuhoa T. Vo, and Hope Rugo, MD.
Where is University of California, San Francisco located?
To reach the University of California, San Francisco hospital:
- Take the SF Muni "T" line towards Sunnyside, disembarking at the UCSF Mission Bay station.
- Alternatively, catch the UCSF "Red" Shuttle from the BART Mission & 16th Street Station, available every 10-15 minutes, Monday-Friday, 6:00 am - 7:50 pm.
- The hospital's address is 505 Parnassus Ave, San Francisco, CA, US.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at UCSF Hospital:
- **Billing:** (866) 433-4035
- **Financial Counseling:** (415) 353-1966
- **Health Insurance:** (415) 353-3333 or (866) 433-4035
These contacts can help with understanding statements, arranging payment plans, and offering financial assistance for qualifying individuals. Visit the UCSF Health website for more details.
What insurance does University of California, San Francisco accept?
The University of California, San Francisco (UCSF) accepts a variety of insurance plans, including HMO plans through Kaiser Permanente, PPO plans through Anthem Blue Cross, Medicare Advantage, and Medi-Cal programs. For employees, UCSF offers medical plans such as Kaiser (HMO), UC Blue & Gold (Health Net), UC Care, UC Health Savings Plan, and CORE (all administered by Anthem Blue Cross). It is crucial to verify with your insurance company or employer's benefit manager for specific plan access to UCSF's services.
What awards or recognition has University of California, San Francisco received?
The University of California, San Francisco (UCSF) hospital is globally recognized for its innovative treatments, advanced technology, and pioneering research in patient care. It is consistently ranked among the top hospitals in the U.S. and California, with several nationally ranked programs for adults and children. UCSF Health has achieved Magnet recognition for nursing excellence since 2012 and is home to five Nobel Prize winners, underscoring its significant contributions to health sciences research.